MichaelThomasMassengillMDPhD

Physician

Dr. Massengill is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Illinois College of Medicine at ChicagoResidency, Ophthalmology, 2020 - 2024
University of Florida College of MedicineClass of 2016

PubMed

223 citations
HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma
Hong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael Massengill
Clinical Cancer Research. 2016-08-15
5 citations
Co-Delivery of a Short-Hairpin RNA and a shRNA-Resistant Replacement Gene with Adeno-Associated Virus: An Allele-Independent Strategy for Autosomal-Dominant Retinal Di...
Michael T. Massengill, Brianna M Young, Alfred S. Lewin, Cristhian J Ildefonso
Methods in Molecular Biology. 2019-01-01
97 citations
Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector.
Artur V. Cideciyan, Raghavi Sudharsan, Valerie L. Dufour, Michael T. Massengill, Simone Iwabe
Proceedings of the National Academy of Sciences of the United States of America. 2018-09-04

Journal Articles

Clinically Relevant Outcome Measures for the I307N Rhodopsin Mouse: A Model of Inducible Autosomal Dominant Retinitis Pigmentosa
Michael Massengill, MD, Investigative Ophthalmology and Visual Science
Mutation-Independent Rhodopsin Gene Therapy by Knockdown and Replacement with a Single AAV Vector
Michael T Massengill, Samuel G Jacobson, Proceedings of the National Academy of Sciences